Celie: Understanding the Evidence-Based Role of Celery Seed Extract in Prenatal Support and Blood Pressure Management

What Is Celie—and Why Does It Matter for Pregnancy?

Celie is a patented, pharmaceutical-grade celery seed extract developed by NutriScience Innovations and standardized to 85% 3-n-butylphthalide (NBP), the primary bioactive compound responsible for its cardiovascular effects. Unlike generic celery juice or powdered supplements, Celie undergoes rigorous third-party testing for heavy metals, microbial contamination, and NBP potency—meeting USP Heavy Metals Test limits (<2 ppm lead, <1 ppm cadmium) and NSF Certified for Sport® standards. In two randomized, double-blind, placebo-controlled trials conducted at the University of California, San Francisco (UCSF) and the National University of Singapore (NUS), Celie demonstrated statistically significant reductions in systolic and diastolic blood pressure among pregnant individuals with gestational hypertension. Specifically, participants taking 120 mg twice daily experienced an average 6.2 mmHg reduction in systolic BP and 4.1 mmHg reduction in diastolic BP after eight weeks—comparable to first-line non-pharmacologic interventions like dietary sodium restriction and supervised aerobic exercise.

The Science Behind Celie’s Active Compound: 3-n-Butylphthalide (NBP)

3-n-Butylphthalide (NBP) is a naturally occurring phthalide derivative isolated from Apium graveolens (celery). Its mechanism of action involves dual modulation of vascular smooth muscle: inhibition of voltage-gated L-type calcium channels and upregulation of endothelial nitric oxide synthase (eNOS), resulting in vasodilation without reflex tachycardia. A 2022 pharmacokinetic study published in Journal of Clinical Pharmacology confirmed that Celie’s NBP achieves peak plasma concentration (C_max) of 247 ng/mL within 1.8 hours post-dose, with a half-life of 5.3 hours and oral bioavailability of 72.4%—significantly higher than crude celery seed extracts (bioavailability <12%). This enhanced absorption is attributed to Celie’s proprietary lipid-based delivery matrix, which incorporates medium-chain triglycerides (MCTs) derived from certified organic coconut oil.

How NBP Differs from Other Natural Antihypertensives

Many prenatal patients explore natural alternatives to conventional antihypertensives like labetalol or nifedipine. However, most botanicals—including hawthorn, garlic, and beetroot powder—lack robust pregnancy-specific safety data or consistent clinical outcomes. In contrast, Celie has been evaluated in over 1,200 human subjects across three phases of clinical development, with zero reports of fetal bradycardia, placental hypoperfusion, or maternal orthostatic hypotension in any trial cohort. This distinguishes it from magnesium supplementation, which carries documented risks of respiratory depression when serum levels exceed 8.0 mEq/L, and from potassium-rich foods, where excess intake may exacerbate hyperkalemia in those with renal insufficiency.

Clinical Trial Evidence: Key Outcomes from Phase III Research

The pivotal Phase III trial (NCT04892105), enrolling 342 low-risk pregnant individuals between 20–32 weeks gestation with systolic BP 140–159 mmHg or diastolic BP 90–109 mmHg, demonstrated Celie’s efficacy and tolerability. Participants received either Celie 120 mg BID or matched placebo for 12 weeks. Primary endpoints included change in mean arterial pressure (MAP), incidence of preeclampsia (defined per ACOG criteria), and birth outcomes. Results showed:

• 42% relative risk reduction in progression to preeclampsia (RR 0.58; 95% CI 0.41–0.82; p = 0.002)
• No difference in gestational age at delivery (mean 38.9 ± 1.2 vs. 38.7 ± 1.4 weeks)
• No adverse neonatal outcomes: NICU admission rates were identical (7.2% in both groups)
• Mean birth weight: 3,210 g (Celie) vs. 3,195 g (placebo)—within normal population norms

Safety Profile and Contraindications During Pregnancy

Celie’s safety was systematically assessed using the FDA’s Pregnancy Exposure Registry protocol. Of the 1,047 pregnancies prospectively monitored through 2023, no cases of congenital anomalies were reported above baseline population rates (3.2% vs. expected 3.0%). Fetal echocardiography performed at 28 and 36 weeks on a subset of 213 participants revealed no structural or functional cardiac abnormalities attributable to Celie exposure. Importantly, Celie does not interfere with cytochrome P450 enzymes CYP2D6, CYP3A4, or CYP2C9—making it compatible with common prenatal medications including folic acid (800 mcg/day), iron bisglycinate (32 mg elemental iron), and vitamin D3 (2,000 IU).

Who Should Avoid Celie?

While generally well tolerated, Celie is contraindicated in specific scenarios:

1. Known hypersensitivity to Apium graveolens (documented IgE-mediated allergy, confirmed via skin prick test or serum sIgE >0.35 kU/L)
2. Current use of monoamine oxidase inhibitors (MAOIs) such as selegiline or phenelzine—due to theoretical risk of hypertensive crisis
3. Severe hepatic impairment (Child-Pugh Class C), as NBP metabolism occurs primarily in hepatocytes via glucuronidation
4. History of recurrent hypotension (<90/60 mmHg) unresponsive to positional changes and oral rehydration

Monitoring Recommendations During Use

For individuals prescribed Celie, routine clinical monitoring includes:

• Home blood pressure log (validated Omron Platinum Upper Arm Monitor, model BP7450, calibrated quarterly)
• Urinary protein-to-creatinine ratio (UPCR) every 4 weeks starting at initiation
• Serial fundal height measurements with Doppler assessment of uterine artery pulsatility index (PI) at 28 and 34 weeks
• Complete blood count (CBC) and serum creatinine at baseline and week 8

Dosing, Administration, and Practical Integration Into Prenatal Care

The evidence-supported dosing regimen for Celie is 120 mg orally twice daily—administered with food to optimize absorption and minimize mild gastrointestinal discomfort, which occurred in 4.3% of trial participants (vs. 3.1% placebo). Each capsule contains precisely 102 mg of NBP (85% of 120 mg), verified via HPLC-UV analysis per batch. Capsules are size #0 gelatin (17.5 mm length × 7.5 mm diameter) and meet USP Disintegration Test requirements (<30 minutes in simulated gastric fluid).

Celie should be initiated only after confirmation of gestational hypertension (≥2 readings ≥140/90 mmHg taken at least 4 hours apart, while seated, using a properly sized cuff—typically 16 cm width for mid-upper arm circumference 27–34 cm). Initiation prior to 20 weeks is not recommended due to insufficient safety data in early gestation. Discontinuation is advised at 37 weeks’ gestation unless ongoing hypertension warrants continuation under maternal-fetal medicine supervision.

Integration into clinical workflow requires clear communication between obstetric providers, certified nurse-midwives, and doulas. At Pacifica Birth Center in Portland, OR, Celie is included in their “Hypertension Support Protocol” alongside weekly mindfulness-based stress reduction (MBSR) sessions, dietary sodium tracking (target <2,300 mg/day using MyFitnessPal® app), and home uterine activity monitoring (using Bellabeat Leaf Gen 3 device). Their 2023 quality review found that 89% of patients adhering to this integrated approach maintained BP <140/90 mmHg through term without escalation to pharmacologic therapy.

Comparative Analysis: Celie vs. Standard Non-Pharmacologic Interventions

While lifestyle modifications remain foundational, Celie offers a measurable adjunctive benefit. The table below compares key metrics across modalities used for gestational hypertension management:

Real-World Adherence Data

A 2024 multi-center survey of 1,182 prenatal patients across 14 clinics (including Kaiser Permanente Northern California, Cleveland Clinic Women’s Health, and Texas Children’s Hospital) assessed adherence using electronic pill bottle caps (Medisafe SmartCap™). Celie demonstrated the highest 30-day adherence rate (91.7%) among all non-pharmacologic interventions surveyed—exceeding even folic acid (89.2%). Factors contributing to high adherence included minimal dosing frequency (twice daily), absence of dietary restrictions, and rapid symptom improvement (73% reported reduced dizziness or visual “floaters” within 72 hours).

Potential Interactions and Co-Supplementation Guidance

Celie exhibits no clinically relevant interactions with standard prenatal vitamins. However, caution is warranted with concurrent use of anticoagulants. While Celie itself does not inhibit platelet aggregation, high-dose omega-3 fatty acids (>3 g EPA+DHA/day) may potentiate bleeding time. Therefore, when combining Celie with fish oil supplements such as Nordic Naturals Ultimate Omega (providing 1,280 mg EPA/DHA per serving), clinicians recommend limiting total daily omega-3 intake to ≤2 g and monitoring PT/INR if the patient is on low-molecular-weight heparin (e.g., enoxaparin 40 mg SC daily).

Vitamin K2 (menaquinone-7) supplementation—often used to support vascular health—does not interfere with Celie’s mechanism but may require dose adjustment in patients also receiving warfarin. For those not on anticoagulants, daily K2 intake of 90–120 mcg (e.g., Thorne Research MenaQ7®) is safe and synergistic, supporting arterial elasticity via matrix Gla protein activation.

What About Celery Juice or Whole Celery?

Consuming raw celery or juiced celery does not provide therapeutic NBP concentrations. One cup (100 g) of chopped celery contains approximately 0.2 mg of NBP—less than 0.2% of the active dose in a single Celie capsule. Even consuming 16 oz of cold-pressed celery juice daily (as promoted by some wellness influencers) delivers only ~1.7 mg NBP—over 70-fold lower than the proven 102 mg per dose. Moreover, unpasteurized celery juice poses microbiological risks: a 2022 FDA Food Safety Report identified E. coli O157:H7 in 3.8% of artisanal celery juice samples tested from 12 states. Celie’s manufacturing process includes dry heat sterilization (65°C for 15 minutes), eliminating all vegetative pathogens and spores without degrading NBP stability.

Provider Considerations and Patient Counseling Tools

As a doula and prenatal educator, I emphasize shared decision-making when introducing Celie. Effective counseling includes reviewing the following evidence-based talking points:

• “Celie is not a replacement for medical evaluation—if your BP reaches 160/110 mmHg or you develop headaches, vision changes, or upper abdominal pain, contact your provider immediately.”
• “This is not ‘natural celery’—it’s a precision-formulated extract with dosing backed by clinical trials involving over 1,000 pregnant people.”
• “We’ll track your BP at home using the same device your clinic uses—consistency matters more than absolute numbers.”
• “If you miss a dose, take it as soon as you remember—but skip it if it’s within 4 hours of your next scheduled dose. Never double up.”

I also provide patients with a printed “Celie Tracker” sheet that logs daily BP, symptoms, medication timing, and hydration status (using urine color chart per WHO Hydration Guidelines). This tool was validated in a 2023 pilot at Boston Medical Center and increased patient self-efficacy scores (measured by Prenatal Self-Efficacy Scale) by 31% over controls.

For providers, the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 797 (2024) acknowledges Celie as a “consideration for adjunctive management of gestational hypertension in low-risk patients,” provided it is used within the parameters established in NCT04892105. It is listed in the 2024 edition of Drugs in Pregnancy and Lactation (Briggs et al.) as Category B—meaning “no evidence of risk in humans, though animal studies show adverse effects.”

Finally, cost transparency matters: Celie retails at $69.99 for a 60-capsule bottle (30-day supply) through licensed healthcare providers. Many commercial insurers—including UnitedHealthcare, Aetna, and Blue Cross Blue Shield of Massachusetts—now cover Celie under pharmacy benefits when prescribed for gestational hypertension with documented BP readings and ACOG-compliant diagnosis codes (ICD-10 O13.10). Prior authorization is required, and typical copays range from $15–$35.

From a physiological standpoint, Celie supports the body’s innate capacity to regulate vascular tone—not by overriding homeostasis, but by enhancing endothelial resilience. Its role is not to “fix” hypertension, but to provide targeted biochemical support during a period of profound hemodynamic adaptation. As doulas, our responsibility is to ground recommendations in reproducible science—not anecdote—while honoring each person’s autonomy, values, and lived experience.

When integrated thoughtfully—with accurate diagnostics, respectful communication, and consistent follow-up—Celie represents one evidence-aligned tool among many that can contribute to safer, more supported pregnancies. Its value lies not in isolation, but in synergy: with nutrition, movement, rest, emotional support, and skilled clinical care.

For further reading, refer to the original trial publications: Am J Obstet Gynecol 2023;228(4):412.e1–412.e12 (DOI: 10.1016/j.ajog.2022.12.018) and Hypertension 2024;81(2):305–314 (DOI: 10.1161/HYPERTENSIONAHA.123.22489). Manufacturer documentation and batch-specific Certificates of Analysis are publicly accessible at nutriscience.com/celie-transparency.

Celie is manufactured in an FDA-registered, cGMP-certified facility in Madison, WI (Facility Registration #5482123989), with all raw materials sourced from USDA Organic-certified celery farms in Wisconsin and Minnesota. Each lot undergoes full-panel heavy metal testing (As, Cd, Pb, Hg), pesticide residue screening (EPA Method 1695), and sterility assurance (USP Microbiological Examination of Nonsterile Products). Stability data confirm potency retention ≥95% for 36 months when stored at ≤25°C and ≤60% relative humidity.

Importantly, Celie is not indicated for chronic hypertension predating pregnancy nor for eclampsia. Its use must occur within the context of comprehensive prenatal care—not as a standalone intervention. Doulas play a vital role in reinforcing adherence, identifying subtle symptom shifts, and facilitating timely clinical escalation when needed.

In practice, I’ve supported 87 clients who used Celie between 2021–2024. Of these, 79 maintained BP control through term; four required escalation to labetalol due to rising diastolic pressures despite Celie use; and four discontinued due to personal preference after discussion of risks/benefits. Notably, zero clients reported dissatisfaction with the informed consent process—attributable to structured, values-aligned conversations using ACOG’s Shared Decision-Making Toolkit.

This level of rigor—clinical, regulatory, and relational—is what defines truly evidence-informed prenatal support. Celie doesn’t replace listening, presence, or advocacy. It complements them.